Lipigon Pharmaceuticals AB (LPGO) — Financial Flexibility Index
Lipigon Pharmaceuticals AB (LPGO) has a Financial Flexibility Index of -1.79x as of December 2025. Free cash flow of Skr-6.38 Million (operating CF Skr-6.38 Million minus capex Skr0.00) represents -2% of total liabilities (Skr3.57 Million). Check LPGO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lipigon Pharmaceuticals AB Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Lipigon Pharmaceuticals AB across 8 annual periods. See LPGO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Lipigon Pharmaceuticals AB (2018–2025)
Year-by-year free cash flow to debt coverage for Lipigon Pharmaceuticals AB. For the full company profile including market capitalisation, see LPGO market cap.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -9.98x | Skr-35.66 Million | Skr-35.77 Million | Skr3.57 Million | ▼ -187.2% |
| 2024 | -3.48x | Skr-24.55 Million | Skr-24.78 Million | Skr7.06 Million | ▼ -25.2% |
| 2023 | -2.78x | Skr-14.32 Million | Skr-14.32 Million | Skr5.16 Million | ▲ +48.5% |
| 2022 | -5.39x | Skr-37.47 Million | Skr-37.47 Million | Skr6.95 Million | ▲ +0.8% |
| 2021 | -5.44x | Skr-35.18 Million | Skr-35.30 Million | Skr6.47 Million | ▼ -44.5% |
| 2020 | -3.77x | Skr-8.51 Million | Skr-8.62 Million | Skr2.26 Million | ▲ +27.9% |
| 2019 | -5.23x | Skr-5.44 Million | Skr-5.56 Million | Skr1.04 Million | ▼ -77.3% |
| 2018 | -2.95x | Skr-3.14 Million | Skr-3.26 Million | Skr1.07 Million | — |